Learn More: Pregnancy and Lactation Studies

This content is intended for healthcare professionals only

Completed Studies

About the CRIB Study

CRIB was a pharmacokinetic study. Evaluating the safety of certolizumab pegol (CZP) was one of the aims on top of assessing the potential level of placental transfer of CZP from pregnant women to their infants. This study followed sixteen women who were at least 30 weeks into their gestation and were already receiving CZP at approved doses.

Click here to access the full study publication

Click here to access a plain language summary

About the CRADLE Study

CRADLE was a pharmacokinetic study. Evaluating the safety of certolizumab pegol (CZP) was one of the aims on top of determining the concentration of CZP in human breast milk and estimating the average daily infant dose, which is the daily dose of maternal CZP ingested by the breastfeeding infant.

Click here to access the full study publication

Click here to access a plain language summary

About the CHERISH Study

The CHERISH study aimed to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies, and safety of CZP throughout pregnancy in participants with chronic inflammatory diseases.

Click here to access pharmacokinetic data from the CHERISH study presented at EULAR 2024

Click here to access a plain language summary